Brief Summary of Prescribing Information for XARELTO® (rivaroxaban)
XARELTO® (rivaroxaban) tablets, for oral use
See package insert for full Prescribing Information
XARELTO® (rivaroxaban) tablets
To reduce the potential risk of bleeding associated with the concurrent
use of rivaroxaban and epidural or spinal anesthesia/analgesia or spinal
puncture, consider the pharmacokinetic profile of rivaroxaban [see
Clinical Pharmacology (12.3) in full Prescribing Information]. Placement
or removal of an epidural catheter or lumbar puncture is best performed
when the anticoagulant effect of rivaroxaban is low; however, the exact
timing to reach a sufficiently low anticoagulant effect in each patient is
not known.
An epidural catheter should not be removed earlier than 18 hours after
the last administration of XARELTO. The next XARELTO dose is not to be
administered earlier than 6 hours af FW"F